文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

院前镇痛使用鼻内氯胺酮(PAIN-K):成人随机双盲试验

Prehospital Analgesia With Intranasal Ketamine (PAIN-K): A Randomized Double-Blind Trial in Adults.
PubMed 文献 · Ann Emerg Med · 2019-03-27
一句话结论在院前一氧化二氮基础上加用鼻内氯胺酮0.75 mg/kg,30分钟时76%患者疼痛评分降低≥2分,优于安慰剂的41%,但不良事件更多。

本研究为随机双盲试验,纳入院前急性疼痛且VNRS评分≥5的成人患者120例,比较鼻内氯胺酮0.75 mg/kg与鼻内生理盐水在常规院前护理(含一氧化二氮)基础上的镇痛效果。主要终点为30分钟时VNRS评分降低≥2分的比例,氯胺酮组76% vs 安慰剂组41%(差值35%,95%CI 17%至51%)。15分钟和30分钟中位VNRS降幅分别为2.0 vs 1.0和3.0 vs 1.0(氯胺酮 vs 安慰剂)。氯胺酮组不良事件报告率62%(95%CI 49%至73%) vs 安慰剂组20%(95%CI 12%至32%),均为轻微不良事件,无需物理或医疗干预。

要点

  • 院前急性疼痛(VNRS≥5)成人,在常规护理和一氧化二氮基础上加用鼻内氯胺酮0.75 mg/kg,30分钟时76%患者VNRS降低≥2分,安慰剂组为41%(差值35%,95%CI 17%至51%)。
  • 15分钟中位VNRS降幅氯胺酮组2.0 vs 安慰剂组1.0,30分钟为3.0 vs 1.0。
  • 15分钟和30分钟报告舒适度改善的比例:氯胺酮组75% vs 安慰剂组57%,以及61% vs 46%。
  • 不良事件报告率氯胺酮组62%(95%CI 49%至73%) vs 安慰剂组20%(95%CI 12%至32%),均为轻微,无患者需要物理或医疗干预。
  • 排除标准包括年龄小于18岁、已知氯胺酮不耐受、非创伤性胸痛、精神状态改变、妊娠和鼻道阻塞。

适用人群与场景

  • 院前急性疼痛成人患者,VNRS疼痛评分≥5,接受常规护理和一氧化二氮。
  • 排除年龄小于18岁、已知氯胺酮不耐受、非创伤性胸痛、精神状态改变、妊娠和鼻道阻塞者。

诊断标准与关键阈值

  • 纳入标准:VNRS疼痛评分≥5。
  • 主要终点:30分钟时VNRS评分降低≥2分的患者比例。

处置流程与药物剂量

  • 在常规护理和一氧化二氮基础上,随机给予鼻内氯胺酮0.75 mg/kg或鼻内生理盐水。

研究设计与关键结果

  • 随机双盲试验纳入120例院前急性疼痛成人,比较鼻内氯胺酮0.75 mg/kg与鼻内生理盐水。
  • 30分钟时VNRS降低≥2分比例:氯胺酮组76% vs 安慰剂组41%(差值35%,95%CI 17%至51%)。
  • 中位VNRS降幅:15分钟氯胺酮组2.0 vs 安慰剂组1.0,30分钟氯胺酮组3.0 vs 安慰剂组1.0。
  • 15分钟和30分钟报告舒适度改善比例:氯胺酮组75% vs 安慰剂组57%,以及61% vs 46%。
  • 不良事件报告率:氯胺酮组62%(95%CI 49%至73%) vs 安慰剂组20%(95%CI 12%至32%),均为轻微,无患者需要物理或医疗干预。

证据类型、等级与局限

  • 证据类型:随机双盲试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于院前急性疼痛成人(VNRS≥5),在常规护理和一氧化二氮基础上加用鼻内氯胺酮0.75 mg/kg可提供临床显著疼痛缓解和舒适度改善,但不良事件更常见,均为轻微且无需干预。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: We compare intranasal ketamine with intranasal placebo in providing pain reduction at 30 minutes when added to usual paramedic care with nitrous oxide.

METHODS: This was a randomized double-blind study of out-of-hospital patients with acute pain who reported a verbal numeric rating scale (VNRS) pain score greater than or equal to 5. Exclusion criteria were younger than 18 years, known ketamine intolerance, nontraumatic chest pain, altered mental status, pregnancy, and nasal occlusion. Patients received usual paramedic care and were randomized to receive either intranasal ketamine or intranasal saline solution at 0.75 mg/kg. The primary outcome was the proportion of patients with VNRS score reduction greater than or equal to 2 at 30 minutes. Secondary outcomes were pain reduction at 15 minutes, patient-reported comfort, satisfaction scores, nitrous oxide consumption, and incidence of adverse events.

RESULTS: One hundred twenty subjects were enrolled. Seventy-six percent of intranasal ketamine patients versus 41% of placebo patients reported a greater than or equal to 2-point VNRS reduction at 30 minutes (difference 35%; 95% confidence interval 17% to 51%). Median VNRS reduction at 15 minutes was 2.0 and 1.0 and at 30 minutes was 3.0 and 1.0 for ketamine and placebo, respectively. Improved comfort at 15 and 30 minutes was reported for 75% versus 57% and 61% versus 46% of ketamine and placebo patients, respectively. Sixty-two percent of patients (95% confidence interval 49% to 73%) versus 20% (95% confidence interval 12% to 32%) reported adverse events with ketamine and placebo, respectively. Adverse events were minor, with no patients requiring physical or medical intervention.

CONCLUSION: Added to nitrous oxide, intranasal ketamine provides clinically significant pain reduction and improved comfort compared with intranasal placebo, with more minor adverse events.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Andolfatto G, Innes K, Dick W, et al. Prehospital Analgesia With Intranasal Ketamine (PAIN-K): A Randomized Double-Blind Trial in Adults. Ann Emerg Med. 2019. PMID: 30926189. doi:10.1016/j.annemergmed.2019.01.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。